GSA Capital Partners’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.57M | Buy |
+2,801
| New | +$1.8M | 0.1% | 256 |
|
|
2025
Q1 | – | Sell |
-717
| Closed | -$296K | – | 1841 |
|
|
2024
Q4 | $296K | Buy |
+717
| New | +$314K | 0.02% | 1214 |
|
|
2024
Q2 | – | Sell |
-2,727
| Closed | -$1.47M | – | 1813 |
|
|
2024
Q1 | $1.47M | Buy |
+2,727
| New | +$1.49M | 0.12% | 234 |
|
|
2023
Q3 | – | Sell |
-5,843
| Closed | -$2.94M | – | 1680 |
|
|
2023
Q2 | $2.94M | Buy |
+5,843
| New | +$2.8M | 0.29% | 13 |
|
|
2023
Q1 | – | Sell |
-789
| Closed | -$322K | – | 1679 |
|
|
2022
Q4 | $322K | Buy |
+789
| New | +$306K | 0.04% | 892 |
|
|
2022
Q3 | – | Sell |
-767
| Closed | -$269K | – | 1685 |
|
|
2022
Q2 | $269K | Buy |
+767
| New | +$313K | 0.04% | 889 |
|
|
2021
Q4 | – | Sell |
-471
| Closed | -$293K | – | 1587 |
|
|
2021
Q3 | $293K | Buy |
+471
| New | +$316K | 0.03% | 1037 |
|
|
2021
Q2 | – | Sell |
-738
| Closed | -$361K | – | 1443 |
|
|
2021
Q1 | $361K | Buy |
+738
| New | +$370K | 0.06% | 535 |
|
|
2020
Q4 | – | Sell |
-1,295
| Closed | -$509K | – | 1388 |
|
|
2020
Q3 | $509K | Buy |
+1,295
| New | +$479K | 0.08% | 379 |
|
|
2020
Q1 | – | Sell |
-2,655
| Closed | -$693K | – | 1282 |
|
|
2019
Q4 | $693K | Buy |
2,655
+1,534
| +137% | +$404K | 0.08% | 431 |
|
|
2019
Q3 | $305K | Buy |
+1,121
| New | +$312K | 0.04% | 879 |
|
|
2018
Q4 | – | Sell |
-12,358
| Closed | -$3.08M | – | 1529 |
|
|
2018
Q3 | $3.08M | Buy |
12,358
+9,178
| +289% | +$2.23M | 0.17% | 88 |
|
|
2018
Q2 | $693K | Sell |
3,180
-1,262
| -28% | -$260K | 0.03% | 968 |
|
|
2018
Q1 | $850K | Sell |
4,442
-3,002
| -40% | -$554K | 0.05% | 767 |
|
|
2017
Q4 | $1.16M | Sell |
7,444
-3,283
| -31% | -$517K | 0.07% | 504 |
|
|
2017
Q3 | $1.67M | Buy |
10,727
+4,688
| +78% | +$741K | 0.11% | 221 |
|
|
2017
Q2 | $975K | Sell |
6,039
-4,963
| -45% | -$806K | 0.06% | 562 |
|
|
2017
Q1 | $1.7M | Sell |
11,002
-2,255
| -17% | -$311K | 0.09% | 330 |
|
|
2016
Q4 | $1.55M | Buy |
13,257
+934
| +8% | +$107K | 0.09% | 315 |
|
|
2016
Q3 | $1.39M | Sell |
12,323
-15,908
| -56% | -$1.68M | 0.07% | 417 |
|
|
2016
Q2 | $2.62M | Buy |
28,231
+18,652
| +195% | +$1.6M | 0.15% | 139 |
|
|
2016
Q1 | $750K | Buy |
+9,579
| New | +$690K | 0.05% | 720 |
|
|
2015
Q3 | – | Sell |
-18,264
| Closed | -$1.17M | – | 1872 |
|
|
2015
Q2 | $1.17M | Sell |
18,264
-6,790
| -27% | -$470K | 0.05% | 762 |
|
|
2015
Q1 | $1.94M | Buy |
25,054
+20,948
| +510% | +$1.63M | 0.08% | 363 |
|
|
2014
Q4 | $304K | Sell |
4,106
-9,728
| -70% | -$682K | 0.02% | 1249 |
|
|
2014
Q3 | $815K | Buy |
+13,834
| New | +$875K | 0.04% | 621 |
|
|
2014
Q1 | – | Sell |
-21,304
| Closed | -$1.13M | – | 1666 |
|
|
2013
Q4 | $1.13M | Buy |
21,304
+9,744
| +84% | +$513K | 0.09% | 290 |
|
|
2013
Q3 | $576K | Sell |
11,560
-492
| -4% | -$23.6K | 0.05% | 695 |
|
|
2013
Q2 | $540K | Buy |
+12,052
| New | +$527K | 0.06% | 500 |
|
Other funds holding IDXX
VCM
VPM
GSA Capital Partners's IDXX Position: Q1 2026 in Review
GSA Capital Partners opened a new position in Idexx Laboratories (IDXX) in Q1 2026: 2,801 shares worth $1.57M. The stake represents 0.1% of the portfolio and ranks #256 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in IDXX as recently as Q4 2024.
GSA Capital Partners first reported a position in IDXX in Q2 2013 and has held it in 29 quarters since. The position peaked at $3.08M in Q3 2018. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- GSA Capital Partners held 2,801 shares of Idexx Laboratories worth $1.57M as of Q1 2026.
- Idexx Laboratories was a new GSA Capital Partners position in Q1 2026.
- Idexx Laboratories made up 0.1% of GSA Capital Partners's portfolio in Q1 2026, its #256 holding.
- GSA Capital Partners first reported a position in Idexx Laboratories in Q2 2013 and has held it in 29 quarters since.
- GSA Capital Partners's Idexx Laboratories position peaked at $3.08M in Q3 2018.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.